Shares of Natera are moving lower after Hindenburg Research issued a short report on the name. “Our findings indicate that Natera has engaged in a grab bag of deceptive billing practices on its quest to satisfy its shareholders’ desires for ever-increasing revenue,” Hindenburg said in a report posted on its website. The firm is also short the stock. Natera’s approach to revenue growth “seems to be reliant on deceiving insurance companies and terrorizing expectant mothers with sticker-shock bills and aggressive collection practices,” contends Hindenburg. The firm says Natera’s tests “just don’t add much value to the health industry ecosystem relative to competitors.” In early trading, shares of Natera are down 19%, or $10.57, to $44.18.